Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
05 Dezembro 2023 - 10:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq:
CPRX) today announced its inclusion in Forbes' esteemed list of
America's Most Successful Small-Cap Companies for the year 2024.
Catalyst has ranked an impressive 4th out of 100 companies on this
prestigious list, which recognizes small-cap companies that have
demonstrated positive sales growth over the last twelve months.
"We are very honored to be recognized among the
top companies in the Forbes 2024 Most Successful Small-Cap
Companies. It is gratifying to receive this prestigious recognition
for the substantial growth we achieved, which is a testament to our
exceptional capabilities,” stated Patrick J. McEnany, Chairman and
CEO of Catalyst. “Our many accomplishments over the past year
reflect the unwavering dedication of all our employees and our
steadfast commitment to the rare disease patient communities we
proudly serve. As we forge ahead, we are resolute in harnessing our
strengths for sustained growth and driving value for our
stakeholders.”
For the ranking, Forbes assessed over 1,000
small-cap companies and narrowed it down to 389 companies that
demonstrated positive sales growth over the past twelve months and
maintained a minimum share price of $5. These stocks were
subsequently ranked based on criteria such as earnings growth,
sales growth, return on equity, and total stock return for the most
recent 12-month period and the preceding five years. Forbes used
data from FactSet to compile its annual list of America’s Most
Successful Small-Cap Companies; all data was as of November 3,
2023.
About Catalyst Pharmaceuticals
With exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's flagship U.S. commercial
product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert Eaton myasthenic syndrome ("LEMS") for
adults and for children ages six to seventeen. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for AGAMREE® (vamorolone) oral suspension 40 mg/mL, a
novel corticosteroid treatment for Duchenne Muscular
Dystrophy. AGAMREE previously received FDA Orphan Drug and
Fast Track designations and was approved by the FDA for
commercialization in the U.S. on October 26,
2023.
For more information about Catalyst
Pharmaceuticals, Inc., visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, visit www.firdapse.com. For Full
Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information
for AGAMREE®, please visit https://www.agamree.com/.
Forward-Looking StatementsThis
press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause Catalyst's actual results in future periods to differ
materially from forecasted results. A number of factors, including
those factors described in Catalyst's Annual Report on Form 10-K
for the fiscal year 2022 and its other filings with the U.S.
Securities and Exchange Commission ("SEC"), could adversely
affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024